Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 552

A team of medical researchers from Shanghai Jiaotong University School of Medicine, Central South University and the Second Affiliated Hospital of Anhui Medical University, all in China, has found evidence suggesting that the placebo effect has grown stronger in trials of transcranial magnetic stimulation therapy for patients treated for depression.

In their study, reported in the journal Nature Mental Health, the group analyzed data from prior research efforts focused on testing the effectiveness of transcranial magnetic therapy.

Prior research has shown that the effect—where a patient is given a “sham” medication or therapy to treat an ailment instead of a real one—can be an effective means of treating some conditions. And while the means by which the placebo effect works is not understood, it has been shown to alleviate symptoms in some people.

Read more | >

A new study in JAMA Network Open may provide key answers to how to help people experiencing chronic back pain.

The study examined the critical connection between the brain and pain for treating chronic pain. Specifically, they looked at the importance of pain attributions, which are people’s beliefs about the underlying causes of their pain, to reduce chronic back pain severity.

“Millions of people are experiencing chronic pain and many haven’t found ways to help with the pain, making it clear that something is missing in the way we’re diagnosing and treating people,” said the study’s first author Yoni Ashar, Ph.D., assistant professor of internal medicine at the University of Colorado Anschutz Medical Campus.

Read more | >

Pancreatic ductal adenocarcinoma (PDAC) presents as an unmet clinical challenge for drug delivery due to its unique hypoxic biology. Vinblastine-N-Oxide (CPD100) is a hypoxia-activated prodrug (HAP) that selectively converts to its parent compound, vinblastine, a potent cytotoxic agent, under oxygen gradient. The study evaluates the efficacy of microfluidics formulated liposomal CPD100 (CPD100Li) in PDAC. CPD100Li were formulated with a size of 95 nm and a polydispersity index of 0.2. CPD100Li was stable for a period of 18 months when freeze-dried at a concentration of 3.55 mg/mL. CPD100 and CPD100Li confirmed selective activation at low oxygen levels in pancreatic cancer cell lines. Moreover, in 3D spheroids, CPD100Li displayed higher penetration and disruption compared to CPD100.

Read more | >

In a recent study published in Science Advances, researchers from the California Institute of Technology, led by Dr. Wei Gao, have developed a machine learning (ML)–powered 3D-printed epifluidic electronic skin for multimodal health surveillance. This wearable platform enables real-time physical and chemical monitoring of health status.

Wearable health devices have the potential to revolutionize the medical world, offering tracking, personalized treatments, and early diagnosis of diseases.

However, one of the main challenges with these devices is that they don’t track data at the molecular level, and their fabrication is challenging. Dr. Gao explained why this served as a motivation for their team.

Read more | >

Lewy body disease ranks as the second most prevalent neurodegenerative disorder, following Alzheimer’s.

Alzheimer’s disease is a disease that attacks the brain, causing a decline in mental ability that worsens over time. It is the most common form of dementia and accounts for 60 to 80 percent of dementia cases. There is no current cure for Alzheimer’s disease, but there are medications that can help ease the symptoms.

Read more | >

Scientists have successfully used nanotechnology to develop a 3D scaffold that supports the growth of healthy retinal cells, a breakthrough that could revolutionize the treatment of age-related macular degeneration (AMD), a leading cause of blindness worldwide. Utilizing electrospinning technology, researchers created a scaffold that, when treated with the steroid fluocinolone acetonide, enhances the resilience and growth of retinal pigment epithelial cells, potentially aiding in the development of ocular tissue for transplantation.

Scientists have discovered a way to use nanotechnology to create a 3D ‘scaffold’ to grow cells from the retina. This breakthrough could lead to innovative approaches for treating a common source of blindness.

Researchers, led by Professor Barbara Pierscionek from Anglia Ruskin University (ARU), have been working on a way to successfully grow retinal pigment epithelial (RPE) cells that stay healthy and viable for up to 150 days. RPE cells sit just outside the neural part of the retina and, when damaged, can cause vision to deteriorate.

Read more | >

ROCHESTER, Minn. — Don’t worry about your hips or knees as you age. Arthritis in those joints isn’t inevitable. Keep doing the activities you enjoy. Those hopeful words come from Rafael Sierra, M.D., an orthopedic surgeon at Mayo Clinic specializing in hip and knee reconstruction. Dr. Sierra says there is no need to curtail your activities out of fear that you’ll wear out those joints as you age and need joint replacement.

However, certain conditions, such as birth defects and anatomical issues, may predispose a person to have hip or knee problems. Untreated, hip dysplasia and hip impingement are leading causes of hip replacement in people under 50. Having bowlegs, knock knees — or other structural issues — can hasten the need for knee replacement.

“But it’s not like the rest of us have to be worried and say, ‘OK, at age 50, maybe I should have my hips or knees examined by a doctor,’” Dr. Sierra says. “In general, your body — your musculoskeletal system — will let you know when you have issues.”

Read more | >

Researchers at Weill Cornell Medicine have discovered that radiation therapy combined with two types of immunotherapy—one that boosts T cells, and another that boosts dendritic cells—can control tumors in preclinical models of triple negative breast cancer, a cancer type that’s typically resistant to immunotherapy alone. Immunotherapy activates the body’s own immune system to fight cancer but isn’t effective for difficult-to-treat “cold” tumors, like this.

The findings were published Aug. 24 in Nature Communications. Though therapy has previously been combined with T-cell boosting immunotherapy, it rarely succeeds in eliminating cold tumors. The new, found that activating another type of immune cell called a dendritic cell, in addition to the other two approaches, produced a synergistic effect that elicited regression.

“I think this is quite exciting,” said principal investigator Dr. Sandra Demaria, professor of radiation oncology at Weill Cornell Medicine and pathologist at NewYork-Presbyterian/Weill Cornell Medical Center, who conducted the research under the auspices of the Department of Radiation Oncology. “There is so much room for improvement to provide more effective therapeutic options, especially for patients with cold tumors.”

Read more | >

Using their new scaffold with cryo-EM, the UCLA-led team saw the atomic structure of KRAS when it was connected to a drug being studied for lung cancer treatment. This showed that their method can help understand how drugs interact with proteins like KRAS, potentially leading to better medicines.

Castells-Graells said, “The potential applications for the new advance don’t stop with cancer drugs. ” Our modular scaffold can be assembled in any configuration to capture and hold all small protein molecules.”

The UCLA-led team’s essential improvement to cryo-EM technology represents a significant milestone in structural biology and scientific imaging. Their achievement in visualizing small therapeutic protein targets at 3 Å resolution is a testament to the power of innovation and collaboration in pushing the boundaries of scientific discovery. This breakthrough promises to revolutionize drug development and our understanding of complex biological systems, further solidifying Cryo-EM’s place as an invaluable tool in modern research.

Read more | >